Arbutus Biopharma reported second quarter 2025 financial results, including a net income of $2.5 million, or $0.01 per basic and diluted common share, a significant improvement from a net loss of $19.8 million in Q2 2024. Total revenue surged to $10.7 million from $1.7 million in the prior year, primarily due to the recognition of previously-deferred revenue following the conclusion of the Qilu Pharmaceutical partnership.
The company continued its cost-cutting efforts, with research and development expenses decreasing by $10.1 million to $5.5 million, and general and administrative expenses falling by $4.2 million to $3.3 million, compared to Q2 2024. These reductions reflect the ongoing organizational streamlining and lower litigation-related legal fees.
Arbutus also announced changes to its Board of Directors and Scientific Advisory Board; Dr. Roger Sawhney joined the Board, while Anuj Hasija resigned, and Dr. Harry Janssen was appointed to the Scientific Advisory Board. As of June 30, 2025, the company held $98.1 million in cash, cash equivalents, and marketable securities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.